An individual project to introduce the iron-deficiency treatment ACCRUFeR® (ferric maltol) to Japan under agreements with ノイファルマ and Shield Therapeutics plc, and to advance clinical development, PMDA approval applications and exclusive sales. It includes the preparation for and conduct of a domestic Phase 2 trial and development progress toward obtaining approval.